Document is current
Any future updates will be listed below
-
Authors
Wang, Shao-bin http://orcid.org/0000-0002-6699-9406
Nagasaka, Yosuke
Argyle, Dionne
Nagasaka, Ayami
Yerramothu, Praveen
Gelfand, Bradley D.
Ambati, Jayakrishna
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY029799, R01EY031039, R01EY028027, R01EY031039)
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
BrightFocus Foundation (M2020114)
- License Information
-
More Information
Article History
Received: 18 August 2022
Revised: 3 November 2022
Accepted: 24 November 2022
First Online: 20 February 2023
Competing interests
: J.A. is a cofounder of iVeena Holdings, iVeena Delivery Systems, and Inflammasome Therapeutics and has been a consultant for Allergan, Boehringer-Ingelheim, Olix Pharmaceuticals, Retinal Solutions, and Saksin LifeSciences unrelated to this work. J.A. and B.D.G. are cofounders of DiceRx. J.A., B.D.G., and S.B.W. are named as inventors on patent applications filed by their university. P.Y.: none; A.N.: none, D.A.: none; Y.N.: none.
: The mouse study protocol was approved by the University of Virginia’s Institutional Animal Care and Use Committee (IACUC, approval number: 4138).
